Euronews is no longer accessible on Internet Explorer. This browser is not updated by Microsoft and does not support the last technical evolutions. We encourage you to use another browser, such as Edge, Safari, Google Chrome or Mozilla Firefox.
BREAKING NEWS

Sanofi to pay Lexicon $260 million for terminated partnership

Sanofi to pay Lexicon $260 million for terminated partnership
FILE PHOTO: The logo of Sanofi is seen at the company's research and production centre in Vitry-sur-Seine, France, August 6, 2019. REUTERS/Charles Platiau -
Copyright
CHARLES PLATIAU(Reuters)
Euronews logo
Text size Aa Aa

(Reuters) – Lexicon Pharmaceuticals Inc <LXRX.O> said on Tuesday France’s Sanofi SA <SASY.PA> will pay the drugmaker $260 million for the termination of their partnership to develop diabetes drug Zynquista.

Shares of Lexicon jumped 37.8% to $2.37 in after hours trading.

Under the terms of the settlement, Sanofi will pay $208 million upfront and the remainder within twelve months to Lexicon, which was eligible to receive up to $1.4 billion in milestone payments under the partnership.

The four-year partnership was terminated by Sanofi in July after the results of three late-stage studies of Zynquista, which is being developed as an add-on to insulin for diabetic patients.

Lexicon will regain global rights for the development and commercialization of Zynquista in both type 1 and type 2 diabetes, the company said in a statement.

The drug has been approved in the European Union for use in type 1 diabetic patients but failed to win U.S. approval in March, months after a panel of experts raised concerns of the risk of diabetic ketoacidosis (DKA).

DKA is a life-threatening condition in which acids called ketones build up when the body starts to use fat instead of glucose as a source of energy.

(Reporting by Saumya Sibi Joseph in Bengaluru; Editing by Shailesh Kuber)

euronews provides breaking news articles from reuters as a service to its readers, but does not edit the articles it publishes. Articles appear on euronews.com for a limited time.